How much does stem cell therapy for Diabetes (Type 1 & 2) cost? (2026)
The comparison dataset stores a Bulgaria planning observation of €3,000–€8,000 for treatment, compiled from cited public commercial sources. It is not a quotation from Stem Plus, and different products, doses, visits and inclusions must not be treated as equivalent. The stored registry query contains 240 Diabetes (Type 1 & 2) records. Registration does not mean that a study is recruiting, that a person is eligible, or that treatment and travel are free; verify the current record and sponsor-cost terms directly.
Type 1 diabetes involves autoimmune loss of insulin-producing beta cells; Type 2 diabetes involves heterogeneous combinations of insulin resistance and beta-cell dysfunction. Research includes stem-cell-derived islets, donor islets, encapsulation, gene editing and immune modulation, but these are distinct technologies with different risks and regulatory status. A generic MSC infusion should not be equated with replacement of functional pancreatic islets.
What drives the cost for Diabetes (Type 1 & 2)
Costs cannot be generalised across routine diabetes care, authorised islet transplantation and investigational cell products. Obtain an itemised estimate for assessment, product, procedure, immunosuppression where applicable, monitoring, travel and complication care. Do not interrupt insulin or other established treatment because an experimental programme is being considered.
FDA-approved Lantidra (donislecel-jujn) is an allogeneic pancreatic-islet cellular therapy made from deceased-donor pancreatic cells for a narrow group of adults with Type 1 diabetes and recurrent severe hypoglycaemia despite intensive management. It is infused into the hepatic portal vein and requires concomitant immunosuppression; it is not a general stem-cell cure for Type 1 or Type 2 diabetes. See the FDA Lantidra record and the NIDDK islet-transplant overview.
Diabetes (Type 1 & 2) cost by country — comparison (2026)
| Location | Indicative treatment cost | Regulation |
|---|---|---|
| Bulgaria (EU) · e.g. Stem Plus | €3,000–€8,000 | Verify provider and laboratory certificates |
| USA | €4,600–€46,000 | Non-EU; verify provider and product status |
| UK | €4,880–€49,000 | Non-EU; verify provider and product status |
| Germany | €11,000–€36,700 | EU member state; verify provider and product status |
| Switzerland | €20,000–€40,000 | Non-EU; verify provider and product status |
| Mexico | €3,000–€12,000 | Non-EU; verify provider and product status |
| India | €3,000–€8,000 | Non-EU; verify provider and product status |
| Serbia | €7,000–€31,000 | Non-EU; verify provider and product status |
| Turkey | €6,000–€18,000 | Non-EU; verify provider and product status |
| Thailand | €8,000–€20,000 | Non-EU; verify provider and product status |
| Panama | €15,000–€27,000 | Non-EU; verify provider and product status |
Price varies with cell type, dose, number of sessions, diagnostics, supportive care and follow-up. A lower range does not establish equivalent quality or outcome. Request a fixed written quote and verify the therapy and provider with the relevant authorities. Check registered trials before paying privately.
Diabetes (Type 1 & 2) cost — common questions
Why is Diabetes (Type 1 & 2) stem-cell treatment so much cheaper in Bulgaria?
The collected commercial ranges differ, but they may describe different products, doses, visits and inclusions. A lower quote does not establish equivalent quality, evidence or regulatory status.
Is a cheaper programme riskier?
Price alone cannot establish risk. Verify the exact treatment status, provider and manufacturing authorisations, product identity, release testing, adverse-event plan and primary evidence.
Does the price include travel and hotel?
The €3,000–€8,000 range covers the medical programme. Add flights, hotel and recovery with our calculator for your true all-in cost from your city.
Will I get a fixed quote, or an open-ended bill?
Ask for a written quotation after clinical review, with the exact product, inclusions, exclusions, cancellation terms and circumstances in which charges may change. A website estimate is not a binding quote.
Sources & further reading
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
- Open clinical trials for Diabetes (Type 1 & 2) (ClinicalTrials.gov) ↗
- Peer-reviewed research on PubMed ↗
- ISSCR patient guide — what to ask ↗
- FDA consumer warning on stem-cell therapies ↗
- EMA — advanced-therapy (ATMP) framework ↗
- Clinic perspective — Stem Plus on Diabetes (Type 1 & 2) ↗
Indicative ranges for planning, compiled from public market data; confirmed pricing follows a medical review. Not medical advice.